Can tick-borne immune responses contribute to neural autoimmunity?

Tick-borne infections can produce neurologic inflammation, but the evidence supports a cautious distinction between biologically plausible autoimmune mechanisms and established clinical autoimmune disease.

Immune mechanisms and clinical relevance

• In selected Borrelia cases, molecular mimicry is directly supported at the cellular level: CD4+ T cells derived from CSF in early Lyme encephalitis recognized both Borrelia peptides and CNS CNPase epitopes. Experimental OspA-homologous peptides have also induced antibodies that stained human neurons, spinal cord, and dorsal-root ganglia.
• These findings provide a credible route by which an antimicrobial response could become neural-antigen directed. They do not establish that such cross-reactivity causes a defined autoimmune neurologic disorder in most people with Lyme disease. Direct comparable molecular-mimicry evidence is not established for other tick-borne microbes.
• Neuroinvasive tick-borne infection can also generate CNS cytokine-mediated immune activation, creating conditions in which bystander activation could lower tolerance to neural antigens. Clinically, however, this process is difficult to distinguish from inflammation caused directly by infection.

Interpreting antibodies and PCR

• Positive antibodies with a negative PCR must be interpreted in clinical context rather than treated as standalone proof of active infection. Borrelia antibodies may persist for years or decades after eradication; single positive ehrlichial or rickettsial IgG results may reflect prior exposure or cross-reactivity.
• Conversely, a negative PCR does not reliably exclude acute infection: yield depends on timing, specimen, and prior doxycycline exposure. When relevant, paired acute and convalescent sera demonstrating a fourfold rise provide stronger evidence of recent infection.

Bottom line

• Molecular mimicry and bystander inflammation are plausible contributors to neural-directed immunity, particularly in selected Borrelia infections, but they do not by themselves establish an autoimmune neurologic diagnosis. Diagnosis and treatment should be driven by the compatible syndrome, exposure and timing, validated testing, and independent evidence for either active infection or autoimmunity.